BIONDVAX PHARMACEUTICALS LTD. Jerusalem BioPark, 2 nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held on

PHARMACEUTICALS LTD.

OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

Be Held on September 2, 2020

Annual General Meeting of Shareholders of BiondVax Pharmaceuticals Ltd. (the "Company") will be held at the offices

of Gross, Kleinhendler, Hodak, Halevy, Greenberg, Shenhav & Co., One Azrieli Center, Tel Aviv 6701101, Israel on September

2, 2020 at 4:00 p.m. Israel time, or at any adjournments thereof (the "General Meeting") for the following purposes:

addition, shareholders at the General Meeting will have an opportunity to review and ask questions regarding the financial statements

of the Company for the fiscal years ended December 31, 2019.

Company is currently unaware of any other matters that may be raised at the General Meeting. Should any other matters be properly

raised at the General Meeting, the persons designated as proxies shall vote according to their own judgment on those matters.

holders of record of ordinary shares, no par value (the "Ordinary Shares"), and holders of record of ADSs, evidenced

by American Depositary Receipts issued by The Bank of New York Mellon, at the close of business on August 3, 2020 shall be entitled

to receive notice of and to vote at the General Meeting (the "Record Date").

Board of Directors recommends that you vote FOR each of the proposals, as specified on the enclosed form of proxy.

or not you plan to attend the General Meeting, it is important that your Ordinary Shares be represented. Accordingly, you are

kindly requested to complete, date, sign and mail the enclosed proxy in the envelope provided at your earliest convenience. Execution

of a proxy will not in any way affect a shareholder's right to attend the General Meeting and vote in person, and any person

giving a proxy has the right to revoke it at any time before it is exercised.

holders should return their proxies by the date set forth on their form of proxy.

either registered in the Company's shareholders' register in Israel or

who hold Ordinary Shares through members of the Tel Aviv Stock Exchange, and who intend to vote their Ordinary Shares either

in person or by proxy, must deliver to the Company's offices, c/o Mr. Uri Ben Or, Chief Financial Officer, at BiondVax

Pharmaceuticals Ltd., Jerusalem BioPark, 2nd Floor, Hadassah Ein Kerem Campus, Jerusalem 9112001, Israel, no later than

September 2, 2020, at 10:00 a.m. Israel time, an ownership certificate confirming their ownership of the Company's

Ordinary Shares on the Record Date, which certificate must be issued or approved by a recognized financial institution, as

required by the Israeli Companies Regulations (Proof of Ownership of Shares for Voting at General Meeting) of 2000, as

amended. Shareholders either registered in the Company's shareholders'

register in Israel or who hold Ordinary Shares through members of the Tel Aviv Stock Exchange may vote through the

attached proxy by completing, dating, signing and mailing the proxy to the Company's offices, c/o Mr. Uri Ben Or at

BiondVax Pharmaceuticals Ltd., Jerusalem BioPark, 2nd Floor, Hadassah Ein Kerem Campus, Jerusalem 9112001, Israel, so that it

is received by the Company no later than August 31, 2020, at 4:00 p.m. Israel time.

Shareholders wishing

to express their position on an agenda item for this General Meeting may do so by submitting a written statement

("Position Statement") to the Company's offices, c/o Mr. Uri Ben Or at BiondVax Pharmaceuticals Ltd.,

Jerusalem BioPark, 2nd Floor, Hadassah Ein Kerem Campus, Jerusalem 9112001, Israel, by no later than August 23, 2020. Any

Position Statement received that is in accordance with the guidelines set by the Companies Law will be furnished to the U.S.

Securities and Exchange Commission (the "Commission") on Form 6-K, and will be made available to the public on

the Commission's website at http://www.sec.gov.

Should no legal quorum be present one-half hour after the scheduled

time, the General Meeting will be adjourned to one week from that day, at the same time and place, i.e. on September 9, 2020,

at 4:00 p.m. (Israel Time) at the offices of Gross, Kleinhendler, Hodak, Halevy, Greenberg, Shenhav & Co., One Azrieli

Center, Tel Aviv 6701101, Israel. Should such legal quorum not be present half an hour after the time set for the adjourned

meeting, any number of shareholders present, in person or by proxy, will constitute a legal quorum.

Notice and the documents mentioned therein, as well as the proposed resolutions on the agenda, can be viewed at the Company's

registered office on Jerusalem BioPark, 2nd Floor, Hadassah Ein Kerem Campus, Jerusalem, Israel, Tel: +972-(8)-930-2529,

Sunday through Thursday between 10:00-15:00, and also will be made available to the public on the Company's website http://www.biondvax.com,

the Commission's website at http://www.sec.gov.